Although the potential effects of anti-RANKL in counteracting chemoresistance or targeted therapy resistance has not been tested, the contact of CLL cells and stromal cells is known to lead to drug resistance (65, 66). This evidence concerns the gene TNFSF11 and B-cell chronic lymphocytic leukemia.